This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

Figure 3: Biosimilars in Emerging Economies, INF Alpha Biosimilars Marketed Outside the US and EU, 2011 14

Figure 4: Biosimilars in Emerging Economies, Biosimilars Comparison With Biologics and Generic, 2012 16

Figure 5: Biosimilars in Emerging Economies, Size and Complexity, Small Molecule Drugs and Proteins, 2012 17

Figure 6: Biosimilars in Emerging Economies, Cost and Timeline for Biosimilar Development, 2011 18

Figure 7: Biosimilars in Emerging Economies, Biosimilars Development, 2011 19

Figure 8: Biosimilars in Emerging Economies, Drivers and Barriers, 2011 20

Figure 9: Biosimilars in Emerging Economies, Top 10 Biologics, 2011 22

Figure 10: Biosimilars in Emerging Economies, Revenue Forecasts ($bn), 2002–2018 24

Figure 11: Biosimilars in Emerging Economies, India, Revenue Forecasts ($bn), 2002–2018 28

Figure 12: Biosimilars in Emerging Economies, DRL, SWOT Analysis, 2012 32

Figure 13: Biosimilars in Emerging Economies, Biocon, SWOT Analysis, 2012 33

Figure 14: Biosimilars in Emerging Economies, IBPL, SWOT Analysis, 2012 35

Figure 15: Biosimilars in Emerging Economies, Reliance Life Sciences, SWOT Analysis, 2012 37

Figure 16: Biosimilars in Emerging Economies, Wockhardt, SWOT Analysis, 2012 38

Figure 17: Biosimilars in Emerging Economies, Lupin, SWOT Analysis, 2012 39

Figure 18: Biosimilars in Emerging Economies, Cipla, SWOT Analysis, 2012 40

Figure 19: Biosimilars in Emerging Economies, China, Revenue Forecasts ($bn), 2002–2018 41

Figure 20: Biosimilars in Emerging Economies, 3SBio, SWOT Analysis, 2012 44

Figure 21: Biosimilars in Emerging Economies, CPGJ, SWOT Analysis, 2012 46

Figure 22: Biosimilars in Emerging Economies, Biotech Pharma, SWOT Analysis, 2012 47

Figure 23: Biosimilars in Emerging Economies, Steps of Risk Management, Turkey, 2012 51

Figure 24: Biosimilars in Emerging Economies, R&D Pipeline by Phase (%), 2011 58

Figure 25: Biosimilars in Emerging Economies, R&D Pipeline by Therapy Class (%), 2011 59

Figure 26: Biosimilars in Emerging Economies, Strategies Adopted By Branded Biologic Companies to Beat Generic Competition, 2011 69

7 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs